OC-048 Filgotinib, a selective jak1 inhibitor, induces clinical remission and a reduction in pstat3 levels in patients with active crohn’s disease: results from the phase ii fitzroy study

S Keshav; J Goh; A Hart; S Levison; S McLaughlin; Avan Aa der; R Galien; Y Pan; L Meuleners; C Jamoul; C Tasset; P Harrison; S Vermeire

doi:10.1136/gutjnl-2017-314472.48

Article info

IBD Section Free Papers

OC-048 Filgotinib, a selective jak1 inhibitor, induces clinical remission and a reduction in pstat3 levels in patients with active crohn’s disease: results from the phase ii fitzroy study

Authors

S Keshav 1Translational Gastroenterology Unit, Experimental Medicine Division, Nuffield Dept of Medicine, John Radcliffe Hospital, Oxford PubMed articles Google scholar articles
J Goh 2Department of Gastroenterology, Queen Elizabeth Hospital Birmingham, Birmingham PubMed articles Google scholar articles
A Hart 3Inflammatory Bowel Disease Unit, St Mark’s Hospital, Middlesex PubMed articles Google scholar articles
S Levison 4Department of Gastroenterology, Manchester Royal Infirmary, Manchester PubMed articles Google scholar articles
S McLaughlin 5Royal Bournemouth Hospital, Bournemouth, UK PubMed articles Google scholar articles
Avan Aa der 6Galapagos NV, Mechelen, Belgium PubMed articles Google scholar articles
R Galien 7Galapagos SASU, Romainville, France PubMed articles Google scholar articles
Y Pan 8Gilead Sciences Inc, Foster City, USA PubMed articles Google scholar articles
L Meuleners 6Galapagos NV, Mechelen, Belgium PubMed articles Google scholar articles
C Jamoul 6Galapagos NV, Mechelen, Belgium PubMed articles Google scholar articles
C Tasset 6Galapagos NV, Mechelen, Belgium PubMed articles Google scholar articles
P Harrison 6Galapagos NV, Mechelen, Belgium PubMed articles Google scholar articles
S Vermeire 9Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium PubMed articles Google scholar articles

Citation

Keshav S, Goh J, Hart A, et al

OC-048 Filgotinib, a selective jak1 inhibitor, induces clinical remission and a reduction in pstat3 levels in patients with active crohn’s disease: results from the phase ii fitzroy study

Gut 2017;66:A25.

Publication history

First published June 17, 2017.

Online issue publication

November 20, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password